Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil)

Japanese Journal of Cancer Research

Volumn 93, Issue 10, 2002, Pages 1145-1153

  Tsukioka, Yoshihisa ^a,c   Matsumura, Yasuhiro ^b   Hamaguchi, Tetsuya ^a   Koike, Hiroyo ^a   Moriyasu, Fuminori ^c   Kakizoe, Tadao ^a  

^a NATIONAL CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Doxil; Doxorubicin; Drug delivery system; NK911; Polymer micelles

Indexed keywords

DOXORUBICIN; DRUG CARRIER; DRUG DERIVATIVE; LIPOSOME; MACROGOL DERIVATIVE; NK911; PEPTIDE; MACROGOL; NK 911; POLYMER;

ARTICLE; CELL STRAIN HT29; CHEMISTRY; DRUG STABILITY; HUMAN; MICELLE; MULTICELLULAR SPHEROID; AQUEOUS SOLUTION; BIOMEDICINE; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; DIFFUSION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; FLUORESCENCE; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; TUMOR VASCULARIZATION;

DOXORUBICIN; DRUG CARRIERS; DRUG STABILITY; HT29 CELLS; HUMANS; LIPOSOMES; MICELLES; PEPTIDES; POLYETHYLENE GLYCOLS; SPHEROIDS, CELLULAR;

EID: 0036807955     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2002.tb01217.x     Document Type: Article

References (32)

1. Matsumura, Y. and Maeda, H. A new concept for macro-molecular therapeutics in cancer chemotherapy: mechanism of turmoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res., 46, 6387-6392 (1986).
2. Maeda, H. and Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst., 6, 193-210 (1989).
3. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1, 27-31 (1995).
4. Dvorak, H. F., Nagy, J. A., Dvorak, J. T. and Dvorak, A. M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol., 133, 95-109 (1988).
5. Matsumura, Y., Kimura, M., Yamamoto, T. and Maeda, H. Involvement of the kinin-generating cascade in enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res., 79, 1327-1334 (1988).
6. Matsumura, Y., Maruo, K., Kimura, M., Yamamoto, T., Konno, T. and Maeda, H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res., 82, 732-741 (1991).
7. Gabizon, A., Chemla, M., Tzemach, D., Horowitz, A. T. and Goren, D. Liposome longevity and stability in circulation: effects on the in vivo delivery to tumor and therapeutic efficacy of encapsulated anthracyclines. J. Drug Target., 3, 391-398 (1996).
8. Sakakibara, T., Chen, F. A., Kida, H., Kunieda, K., Cuenca, R. E., Martin, F. J. and Bankert, R. B. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res., 56, 3743-3746 (1996).
9. Lasic, D. D. Doxorubicin in sterically stabilized liposomes. Nature, 380, 561-562 (1996).
10. Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A. and Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res., 54, 987-992 (1994).
11. Northfelt, D. W., Dezube, B. J., Thommes, J. A., Miller, B. J., Fischl, M. A., Friedman-Kien, A., Kaplan, L. D., Du Mond, C., Mamelok, R. D. and Henry, D. H. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol., 16, 2445-2451 (1998).
12. Stewart, S., Jablonowski, H., Goebel, F. D., Arasteh, K., Spittle, M., Rios, A., Aboulafia, D., Galleshaw, J. and Dezube, B. J. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International pegylated liposomal doxorubicin study group. J. Clin. Oncol., 16, 683-691 (1998).
13. Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E. and Lacave, A. J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol., 19, 3312-3322 (2001).
14. Harrington, K. J., Mohammadtaghi, S., Uster, P. S., Glass, D., Peters, A. M., Vile, R. G. and Stewart, J. S. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res., 7, 243-254 (2001).
15. Yokoyama, M., Miyauchi, M., Yamada, N., Okano, T., Sakurai, Y., Kataoka, K. and Inoue, S. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res., 50, 1693-1700 (1990).
16. Yokoyama, M., Fukushima, S., Uehara, R., Okamoto, K., Kataoka, K., Sakurai, Y. and Okano, T. Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. J. Controlled Release, 50, 79-92 (1998).
17. Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y. and Kataoka, K. Development of the polymer micelle carrier system for doxorubicin. J. Controlled Release, 74, 295-302 (2001).
18. Konno, T., Maeda, H., Iwai, K., Maki, S., Tashiro, S., Uchida, M. and Miyauchi, Y. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer, 54, 2367-2374 (1984).
19. Yoshimoto, T., Nishimura, H., Saito, Y., Sakurai, K., Kamisaki, Y., Wada, H., Sako, M., Tsujino, G. and Inaba, Y. Characterization of polyethylene glycol-modified L-asparaginase from Escherichia coli and its application to therapy of leukemia. Jpn. J. Cancer Res., 77, 1264-1270 (1986).
20. Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., Tkaczuk, K., Park, Y. C. and Lee, L. W. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol., 19, 1444-1454 (2001).
21. Gill, P. S., Wernz, J., Scadden, D. T., Cohen, P., Mukwaya, G. M., von Roenn, J. H., Jacobs, M., Kempin, S., Siverberg, I., Gonzales, G., Rarick, M. U., Myers, A. M., Shepherd, F., Sawka, C., Pike, M. C. and Ross, M. E. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J. Clin. Oncol., 14, 2353-2364 (1996).
22. 2. Ann. Oncol. 11, 1029-1033 (2000).
23. Bader, H., Ringsdorf, H. and Schmidt, B. Water-soluble polymers in medicine. Angew. Macromol. Chem. 123/124, 457-485 (1984).
24. Gabizon, A., Shiota, R. and Papahadjopoulos, D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 81, 1484-1488 (1989).
25. Vaage J, Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer, 73, 1478-1484 (1994).
26. Jain, R. K. Barriers to drug deliverity in solid tumors. Sci. Am., 271, 58-65 (1994).
27. Hong, R. L., Huang, C. J., Tseng, Y. L., Pang, V. F., Chen, S. T., Liu, J. J. and Chang, F. H. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? Clin. Cancer Res., 5, 3645-3652 (1999).
28. Unezaki, S., Maruyama, K., Hosoda, J., Nagae, I., Koyanagi, Y., Nakata, M., Ishida, O., Iwatsuru, M. and Tsuchiya, S. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo flourescence microscopy. Int. J. Pharm. 144, 11-17 (1996).
29. Mizumura, Y., Matsumura, Y., Hamaguchi, T., Nishiyama, N., Kataoka, K., Kawaguchi, T., Hrushesky, W. J. M., Moriyasu, F. and Kakizoe, T. Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity. Jpn. J. Cancer Res., 92, 328-336 (2001).
30. Hamaguchi, T., Matsumura, Y., Shimoyama, T., Kakizoe T., Yokoyama, M., Okano, T., Kataoka, K. and Ogawa, Y. Polymeric micellar paclitaxel enhances in vivo antitumor activity while reducing neurotoxicity (abstr.). Proc. Int. Symp. Polym. Ther., 29 (2001).
31. Matsumura, Y., Yokoyama, M., Kataoka, K., Okano, T., Sakurai, Y., Kawaguchi, T. and Kakizoe, T. Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn. J. Cancer Res., 90, 122-128 (1999).
32. Kataoka, K., Togawa, H., Harada, A., Yasugi, K., Matsumoto, T. and Katayose, S. Spontaneous formation of polyion complex micelles with narrow distribution from antisense oligonucleotide and cationic block copolymer in phusiological saline. Macromolecules, 29, 8556-8557 (1996).